MedPath

Endoscopic Gastric Tubulization

Recruiting
Conditions
Morbid Obesity
Interventions
Procedure: Endoscopic gastric tubulization
Registration Number
NCT03554902
Lead Sponsor
IHU Strasbourg
Brief Summary

Endoscopic gastric tubulization is currently proposed in the Digestive Surgery Department of the Nouvel Hôpital Civil, Strasbourg, France, to adult patients with morbid obesity. The procedure is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA). It is standard practice since October 2016.

The objective of this study is to prospectively collect data of patients who underwent an endoscopic gastric tubulization, from last visit before procedure to 2 years after procedure. These data are usually collected during medical consultations and will enable the evaluation of weight loss, quality of life and comorbidities improvement, reproducibility and durability of the technique.

Detailed Description

Gastric restriction is one of the fundamental principles of gastric bypass and gastric banding. Despite its advantages (long term weight loss, comorbidities related to obesity improvement...), bariatric surgery is risky. In fact, complications putting the patient into a life-threatening condition can occur. Endoscopic approaches are similar to current surgical methods but less invasive, safer and allow ambulatory care.

Nowadays, practitioners have the possibility to reduce stomach size by merging tissues through an endoscopic endoluminal suture approach without any incision. This leads to similar results (gastric restriction, weight loss, quality of life and comorbidities improvement) compared with standard surgical procedure while reducing the risk of complications.

One of the major benefit of this technique is its reversibility. A new surgical or endoscopic procedure is possible at a later stage.

Endoscopic gastric tubulization is currently proposed in the Digestive Surgery Department of the Nouvel Hôpital Civil, Strasbourg, France, to adult patients with morbid obesity. The procedure is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA). It is standard practice since October 2016.

The objective of this study is to prospectively collect data of patients who underwent an endoscopic gastric tubulization, from last visit before procedure to 2 years after procedure. These data are usually collected during medical consultations and will enable the evaluation of weight loss, quality of life and comorbidities improvement, reproducibility and durability of the technique.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Patients scheduled for an endoscopic gastric tubulization in the Nouvel Hôpital Civil, Strasbourg, France
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Endoscopic gastric tubulizationEndoscopic gastric tubulizationEndoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
Primary Outcome Measures
NameTimeMethod
Change in weight loss7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure

Change in weight loss measured in kilograms.

Change in body mass index variation7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure

Change in body mass index variation measured in kg/m².

Change in excess weight loss7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure

Change in excess weight loss measured in percentage. Excess weight loss = (weight loss at time point / weight loss goal to reach a body mass index of 25 kg/m²) x 100

Secondary Outcome Measures
NameTimeMethod
Procedure durationAt time of procedure

Time required to perform the endoscopic gastric tubulization.

Number of patients with procedure-related adverse event7 days, 1 - 3 - 6 - 9 and 12 months after procedure

Number of patients with procedure-related adverse event within 12 months after procedure.

Comorbidities improvement7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure

Improvement of sleep apnea, arterial hypertension, diabetes, reflux, osteoarticular disorders compared with preoperative data.

Quality of life improvement3 - 12 - 18 and 24 months after procedure

Improvement of quality of life assessed by Moorehead-Ardelt Quality of Life questionnaire II. Score range from -3.0 to 3.0.

* Score from -3.0 to -2.1: very poor quality of life

* Score from -2.0 to -1.1: poor quality of life

* Score from -1.0 to 1.0: fair quality of life

* Score from 1.1 to 2.0: good quality of life

* Score from 2.1 to 3.0: very good quality of life.

Gastro-intestinal quality of life improvement3 - 12 - 18 and 24 months after procedure

Improvement of quality of life assessed by the Gastro-Intestinal Quality of Life Index questionnaire. A global score \> 125 is considered as normal.

Modification in the feeling of satiety1 - 3 - 6 - 12 - 18 and 24 months after procedure

Satiety assessed by Three Factors Eating Questionnaire - R18. Three dimensions are assessed. The higher the score is, the more important the dimension is.

* Restrained eating: score from 6 to 24

* Uncontrolled eating: score from 9 to 36

* Emotional eating: score from 3 to 12.

Upper GI tract radiologic evaluation1 day, 6 - 12 and 24 months after procedure

Upper GI control series.

Upper GI tract endoscopic evaluation6 - 12 and 24 months after procedure

Upper GI control gastroscopy.

Number of stitches in placeAt time of procedure

Number of stitches put in place during the endoscopic gastric tubulization.

Trial Locations

Locations (1)

Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil

🇫🇷

Strasbourg, France

© Copyright 2025. All Rights Reserved by MedPath